Breakthrough bacteremia and meningitis during treatment with cephalosporins parenterally for pneumococcal pneumonia.
An extended-spectrum cephalosporin has been considered appropriate therapy for non-meningeal infections caused by drug-resistant Streptococcus pneumoniae. We report a toddler who had breakthrough bacteremia and meningitis develop because of drug-resistant pneumococcus while receiving treatment with cefotaxime and cefuroxime for pneumonia.
Buckingham
S C
SC
Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, USA.
Brown
S P
SP
Joaquin
V H
VH
D016470:Bacteremia / Q000150:complications / Q000209:etiology*; D002439:Cefotaxime / Q000008:administration & dosage / Q000627:therapeutic use; D002444:Cefuroxime / Q000008:administration & dosage / Q000627:therapeutic use; D018550:Cephalosporin Resistance; D002511:Cephalosporins / Q000008:administration & dosage / Q000627:therapeutic use*; D018432:Drug Resistance, Multiple; D006801:Humans; D007223:Infant; D007262:Infusions, Intravenous; D008297:Male; D008586:Meningitis, Pneumococcal / Q000150:complications / Q000209:etiology*; D011018:Pneumonia, Pneumococcal / Q000150:complications* / Q000188:drug therapy*; D013296:Streptococcus pneumoniae / Q000187:drug effects*
D002511:Cephalosporins; D002439:Cefotaxime; D002444:Cefuroxime